Rhenman & Partners Asset Management AB Cuts Position in Bruker Co. (NASDAQ:BRKR)

Rhenman & Partners Asset Management AB decreased its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 18.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,315 shares of the medical research company's stock after selling 8,000 shares during the quarter. Rhenman & Partners Asset Management AB's holdings in Bruker were worth $2,129,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of BRKR. State Street Corp increased its holdings in shares of Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock worth $250,501,000 after buying an additional 318,808 shares during the last quarter. Geode Capital Management LLC increased its stake in Bruker by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 2,013,741 shares of the medical research company's stock valued at $118,081,000 after acquiring an additional 20,273 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its position in Bruker by 140.3% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock valued at $66,930,000 after purchasing an additional 666,617 shares in the last quarter. Norges Bank bought a new stake in Bruker during the fourth quarter worth about $63,378,000. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Bruker by 7.6% in the 4th quarter. Bank of New York Mellon Corp now owns 988,863 shares of the medical research company's stock worth $57,967,000 after purchasing an additional 69,806 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Bruker Trading Down 10.1 %

BRKR stock traded down $4.17 on Thursday, reaching $37.02. The company's stock had a trading volume of 1,956,637 shares, compared to its average volume of 1,447,272. The firm has a market cap of $5.62 billion, a PE ratio of 48.41, a PEG ratio of 2.16 and a beta of 1.18. The business has a fifty day simple moving average of $46.89 and a two-hundred day simple moving average of $55.16. Bruker Co. has a 12-month low of $34.10 and a 12-month high of $90.56. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. As a group, research analysts forecast that Bruker Co. will post 2.69 EPS for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Monday, March 17th were given a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.54%. Bruker's dividend payout ratio is presently 26.32%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of a number of recent research reports. Guggenheim restated a "buy" rating on shares of Bruker in a research report on Monday, February 24th. Barclays cut their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating for the company in a research note on Thursday. Stifel Nicolaus decreased their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Citigroup cut their price target on shares of Bruker from $75.00 to $50.00 and set a "buy" rating for the company in a research report on Monday. Finally, Bank of America boosted their target price on Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $66.50.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.